III. Conclusion
Of the several thousand fermentation products which had been described until the discovery of avermectins, several compounds, anthelmycin1}, anthelvencins2), aspiculomycin3), axenomycins4), G-4185), hygromycin B6), destomycin A7), paromomycin8), and thaimycins9), were reported to possess anthelmintic activity. Only aminoglycoside antibiotics, hygromycin B, destomycin A and paromomycin, have been used as antiparasitic drugs in actual, whereas, synthetic compounds dominated the anthelmintic market. The discovery of the avermectins changed the market dramatically because the compoundsare potent antiparasitic compoundswith a broad spectrum activity against nematode and arthropod parasites in spite of lacking antibacterial and antifungal activities. Its dosage for animal and human is extremely low as well.
"Ivermectin", a semisynthetic avermectin, whichis a hydrogenated product of avermectin Bl has been introduced to the market as an antiparasitic agent in 198 1 , and as an agricultural pesticide and an antiparasitic 549 agent in 1985. The efficacy of ivermectin against nematode and arthropod parasites is unprecedented in potency and breadth of spectrum. Ivermectin is used for livestock production and the health care of companion animals. The efficacy of ivermectin in human onchocerciasis has made it a promising candidate for the control of one of the most insidious and intractable of tropical diseases10). Recently, ivermectin has been found to be effective for the treatment of human disease strongyloidiasis in Okinawa Prefecture, Japan1 1}.
Avermectins produced by Streptomyces avermitilis which was isolated from a soil sample collected at Kawana, Ito City, Shizuoka Prefecture, Japan are a complex of eight of sixteen-membered macrocyclic lactones substituted with a disaccharide of L-oleandrose, resulting from structural differences at three positions, C-5, C-22-23, and C-26 (Fig. l)12~14 ).
Among these components, Bl fraction has the most effective antiparasitic activity15).
Since the industrial separation of Bla and Bib in the Bl fraction is quite diffi-
Both sugars are a-L-oleandrose. Ivermectin is chemically synthesized from avermectin Bl components (Bla and Bib) by selective hydrogenation and commercial product of ivermectin consists of more than 80%of ivermectin Bla and less than 20% of ivermectin Bib. cult, the commercial product contains more than 80%
of Bla and less than 20% of Bib components. Although S. avermitilis produces eight components of avermectins, only two components, Bla and Bib, are available for the medical, veterinary and agricultural fields. Furthermore, the microorganism produces not only avermectins but also oligomycin (Fig. 2) , a polyketide antibiotic, that is a specific inhibitor for the oxidative-phosphorylation system in mammaliancells.
In general, most of microbial secondary metabolites, including bioactive compounds, are produced as closely related complex by their producing microorganisms. Macrolide compounds, including avermectins and their related compounds1 7~20), are typical examples produced in such a manner. As a reason that such producing microorganisms produce many components, it is considered that the biosynthesis of these compoundsis more complex and/or the enzyme(s) involving in their biosynthetic step(s) possesses lower substrate specificity and, therefore, has an ability to catalyze related substrates.
Thus, there are some problems for the efficient production of useful component( propionates and one branched-chain fatty acid by using corresponding 1 3C-labeled compounds. The 2-methylbutyryl residue (C25-C28) of the "a" components and the isobutyryl residue (C25-C27) of the "b" components were not labeled by either acetate or propionate. They were derived from L-isoleucine and L-valine, respectively23'241. This finding was supported by the efficient incorporation ofL-isoleucine into the "a" components and L-valine into the "b" components. Furthermore, C25 of avermectin Bla was highly enriched by feeding of [1-13C] 2-methylbutyrate and that of avermectin Bib by [1-13C] isobutyrate24). The origin of the oxygen atoms in the lactone was investigated by measuring the incorporation of 18O-labeled-acetate and -propionate22). The oxygens at Cl, C5, C7, C13, C17, C19, andC23 (forthe "2" components) retained their isotope content. The oxygen at C21 would be probably derived from the 2-methylbutyryl or isobutyryl side chain, but the oxygen in the benzofuran between C6 and C8a was not. Although the origin of the oxygen of furan ring in other metabolites has not been investigated, that in the avermectins is seemed to be derived from "molecular oxygen". The studies with labeled glucose indicated that glucose converted directly to oleandrose, and this finding was supported by studies with [1-13C] glucose and [U-13C] glucose, showing high enrichment of the oleandrose units25).
Three methoxy groups at C5, C3' and C3" in avermectin have been confirmed to be derived from methyl residue of L-methionine by labeling experiments24^Figure 3 summarizesthe results obtained from the incorporation studies with labeled precursors.
B. Biosynthetically Blocked Mutants and Characteristics of Each Step in Avermectin Biosynthetic Pathway
Several kinds ofbiosynthetically blocked mutants were isolated by us21) and Merck group24), independently.
These mutants were classified into two types as follows; mutation in the early stage of biosynthesis (formation of 6,8a-seco-6,8a-deoxy-5-oxoavermectin aglycone) and mutation in the late stage ofbiosynthesis (after formation of aglycone; modifying aglycone). By the analyses of products accumulated by the mutants and conversions ofintermediates, the nathwav for avermectin biosvnthesis This class of mutation is in the step(s) of formation of aglycone (polyketide synthase) and the mutants did not yield any avermectin compounds26), however, the mutants have ability to convert 6,8a-seco-6,8a-deoxy-5-oxoavermectin aglycones or avermectin aglycones to natural avermectins26'2 7).
aveB (step for glycosylation)
The aveB mutants produce avermectin aglycones, indicating that the mutation affected in the step of glycosylation26).
Avermectin aglycone glycosyltransferase, which catalyzes the stepwise addition of oleandrose units from the nucleotide sugar thymidine diphosphate oleandrose28) (dTDP-oleandrose) to the avermectin aglycone, is demonstrated in cell-free extract24).
3. aveC (step for C22-23-dehydration) This type of mutants produce "2" components of 4. aveD (step for C5 Omethylation) The mutants produce "B" componentsof avermectins30).
The mutants lack the enzyme activity of avermectin B 0-methyltransferase, which catalyzes the conversion of "B" components to "A" components by transferring the methyl of S-adenosyl-L-methionine to the C5 hydroxyl of the "B" components, yielding the "A" components and »S-adenosyl-L-homocysteine31).
This enzyme with the molecular weight of 70,000 was purified and characterized the substrate specificity for the avermectins, in order of decreasing activity, is as follows:
B2a aglycone>B2a monosaccharide>Bla aglycone>Bla monosaccharide>B2a>Bla. The "2" componentsreact faster than "1" componentsand there was virtually no activity detected with avermectin Bla as substrate24).
5. aveE (step for furan ring formation at C6 to C8a) The mutants produce 6,8a-seco-6,8a-deoxyavermectin derivatives causing the mutation in the step of furan ring formation at C6 to C8a27 '32) . AveE mutants isolated by us and Merck group, independently, produced several kinds of compounds lacking furan ring consisted of avermectin aglycones, monosaccharides, and disaccharides (Fig. 5) . Furthermore, some of compounds had keto group at C5 position.
Probably, 6,8a-seco-6,8a- . Structures of 6,8a-seco-6,8a-deoxy derivatives produced by aveE mutants.
deoxyavermectin derivatives produced by the mutants would not be suitable substrates for glycosylation and C5 keto reduction. Feeding of 6,8a-seco-6,8a-deoxyavermectin derivatives to aveA mutant culture27) or the wild type culture supplemented with cerulenin revealed that these aglycones are converted to monosaccharide and disaccharide lacking furan ring at C6 to C8, but not to natural avermectins, although other aglycones such as, 6,8a-seco-6,8a-deoxy-5-oxo derivatives are converted to natural avermectins.
aveF (step for C5 keto reduction)
Although many attempts for the isolation of this type of mutants by mutagenesis have been done by us and Merck group, the mutants affecting C5 keto reduction have not been isolated. Furthermore, the C5 keto reductase which catalyzes the NADPH specific reduction of 5-oxoavermectins to "B" componentshas been demonstrated in cell-free extract of S. avermitilis2^.
Recently, we isolated aveF mutants by genetic engineering33). The mutants produce 5-oxoavermectins, but not either aglycones or monosaccharides. From the results of conversion of the derivatives lacking furan ring at C6
Ri R2
to C8a27), the reduction of C5 keto residue must occur after furan ring formation at C6 to C8a in ordinary biosynthesis.
aveR (step for regulation of biosynthesis)
The aveRmutants showedthe samephenotype as that of aveA mutants which do not produce any avermectins, however, aveR mutants did not have the ability to convert any intermediates which were generated after the formation of aglycones to the natural avermectins34 '35) . This meansthat the mutation would cause to suppress expression of the formation ofaglycones and the followed steps, including furan ring formation at C6 to C8a, C5 keto reduction, stepwise glycosylation at C13 and C4', and C5 0-methylation.
From these results the aveR mutant was defined as regulatory mutant in avermectin biosynthesis.
8. X(step concerning selective incorporation of branched-chain fatty acid into avermectin aglycones) It has been shown that the substituent groups of the "a" and "b" components at C25 are derived from L-isoleucine and L-valine, respectively23'24^The mutants accumulate avermectins "a" components but not "b" components21>23). Since the biochemical and genetic characteristics of the mutant were unclear, the genotype was designed as X. It seemed that the mutant could incorporated L-isoleucine into the avermectin aglycone but not L-valine. Consequently the incorporation of L-isoleucine, L-valine and corresponding keto acids, 3-methyl-2-oxovalerate and 2-oxoisovalerate provided through the deamination or transamination of lisoleucine and L-valine, respectively, into the avermectin aglycone was examined in both parent and mutant strains21'23).
The both branched-chain amino and keto acids were efficiently incorporated into the avermectin aglycones in the wild type strain. In the case of mutants, the incorporation of L-isoleucine and its keto acid was efficient, but that ofL-valine and its keto acid was scarcely incorporated into avermectin aglycones, suggesting that since the incorporation of L-valine or its keto acid into the avermectin aglycone was markedly suppressed in the mutants, the mutants accumulated avermectin "a" components.
Inhibition of enzyme reaction involving biosynthesis by specific inhibitors has made it possible to block specific step in the biosynthetic pathway as well as a biosynthetically blocked mutants. Cerulenin is a potent inhibitor of fatty acid and polyketide syntheses and has been shown to inhibit formation of avermectin aglycones in vivo without affecting to biosynthetic steps after it, which is the samemanneras that of a biosynthetically blocked mutant aveA. It has been confirmed that the conversion of intermediates was efficiently proceeded by the culture of wild-type producer supplemented with cerulenin as described above.
On the other hand, sinefungin, an analogue of S-adenosyl-L-methionine, is a potent inhibitor of methyltransferases and has been shown to inhibit C5 (9-methylation in vitro36). Feeding to a culture of aveB mutant, which produces only the avermectin aglycone of the "A" components, sinefungin inhibited the formation of the "A" components and caused a goncominant accumulation of the avermectin aglycone of the "B" components30). Furthermore, sinefungin inhibited not only C5 O-methylation but also both C3' and C3" O-methylations.
New components lacking methoxy groups on the C3' and C3" of the oleandrose were accumulated by adding sinefungin to the wild type culture30).
The result indicates that both C3' and C3" condensations are required to incorporate seven acetate, five propionate and one branched-chain fatty acid units into avermectin aglycone22'24). It is likely that each of the twelve modules encodes a synthase unit specific for each of twelve condensation steps.
An llkbp subclone from the right end of the gene cluster for avermectin biosynthesis restored normal avermectin biosynthesis for all mutants defective in glycosylation of avermectin35). A 9kbp region of the 1 1 kbp subclone was responsible for both synthesis and attachment of oleandrose disaccharide. There are eight putative open reading frames in the 9kbp region. Potential functions of several frames of these were identified to be consistent with a proposed pathway for the conversion of glucose to dTDP-oleandrose, including steps for both C3' and C3" O-methylations. A 4.82kbp subclone from the central region in the gene cluster restored partially avermectin biosynthesis in two types of mutants defective C22-23 dehydration (aveC) and C6-8a furan ring formation (aveE)32). DNA sequencing of this 4.82 kbp segment indicated that aveC and aveE form operons with aveAI and aveAII, respectively.
About 14kbp region at the left end of the gene cluster was encoded both functions for C5 keto reduction and C5 (9-methylation40) and for positive regulation of avermectin biosynthesis. The strains with deletion and insertion in about 10kbp region at the left end of the cluster did not methylate or glycosylate the substrates of avermectin even though the structural genes for these functions did not have mutation. The pleiotropic phenotype of these mutants suggested that they lack a positive regulatory function necessary to turn on expression of all the genes involved in avermectin biosynthesis.
A 3.4kbp-itamHI segment encoded domains of C5 keto reduction and C5 O-methylation, and these two genes would be transcribed polycistronically33'43). The time courses of expression of the both enzymeactivities for C5 O-methylation and C5 keto reduction and avermectin production were measured in a number of high-yielding strains of S. avermitilis. The maximum specific activities of these enzymes increased in direct proportion to the quantity of avermectin formed. The results support the hypothesis that genes coding for enzymes involved in the biosynthesis of the secondary metabolites would be coordinately expressed and regulated.
II. Application to the Selective Production of Useful Component(s)
Although S. avermitilis produces eight related components of avermectins, only two components (Fig. 8) , Bla and Bib, are used in medical, veterinary and agricultural field, in which the industrial separation is difficult. Furthermore, the organism produces also an unwanted toxic compound, oligomycin. Thus, some problems remain unsolved for the industrial production of avermectin Bla, the most effective component.
A. Production of Specific Component(s)
The knowledge ofbiosynthetic pathway of avermectins makes it possible to construct the producer of specific component(s), who produces them by suppression of some steps without affecting other steps in avermectin biosynthesis.
Selective Production of Avermectins Bla and B2a
Weisolated several types of mutants affecting the production of avermectins. Amongof them, two mutants, K2021 and K203423) produce only the specific components (Fig. 9) . The strain K2034 produces "B"
components alone, namely components Bla, Bib, B2a, Retention Time (min)
The mycelia from 10 ml-culture were extracted with equal volume of methanol for 15 minutes. A portion of the extract was directly applied to reversed phase silica gel HPLC. The separation conditions were described in ref. 23. and B2b. Accumulation of the "B" components in the mutant K2034 is due to lack of the ability of conversion of the components "B" to the "A", whose genotype is defined as aveD. Another mutant K2021 produces four "a" components, Ala, A2a, Bla, and B2a, but not the "b" components, of which genotype is defined as X. This mutant accumulates the "a" componentsbecause the incorporation of L-valine into the avermectin aglycone is markedly suppressed. Therefore, if a strain possessing both phenotypes of the two mutants, K2021 and K2034, can be designed, it should produce only the components Bla and B2a. In the studies of the genetic crossing and mapping of S. avermitilis, the recombination frequency was about 10"5 to 10"7 by mixed culture26*. But the frequency was dramatically increased to about 10~2 by a protoplast fusion in the presence of polyethylene glycol.
Moreover, although the multiple crossover in recombinants derived from the mixed culture of spores was scarcely observed, the quadruple or more multiple crossover was detected in the recombinants derived from the protoplast fusion. Therefore, recombinants derived from crossing between closely related two loci on the chromosomewould be recovered by the protoplast fusion. In consideration of this view, we tried to isolate the recombinants possessing both phenotypes by protoplast fusion23). Protoplasts of the two mutants were prepared and fused in the presence of 40% (w/v) polyethylene glycol MW,1,000. The protoplasts fused were regenerated to mycelial form with growing on a regeneration medium and the expected recombinants were obtained efficiently without any selection. Eight recombinants out of 192 colonies screened produced The extraction of products and separation conditions were described in Fig. 8 . Retention Time (min)
The extraction of products and separation conditions were described in Fig. 8 .
avermectins
Bla and B2a (Fig.  10) .
Since the recombination frequency of crossing between auxotrophic markers was about 10~2 by the protoplast fusion, the recombinants possessing both selective producing phenotypes (aveD and X) were isolated efficiently. We have determined the locus ofXmutation on the genome. From the result of genetic mapping, the locus of X mutation was distant enough from that of the gene cluster for avermectin biosynthesis on the genome29). This fact suggests that one of the genes involving in the selective production of the specific components of avermectins might concern the catabolism of branched-chain amino acids, rather than involved directly in avermectin biosynthesis.
Selective Production of 5-Oxoavermectins Bla and

B2a
A large number of avermectin derivatives have been made by variety of techniques, including mutagenesis44), biotransformation45), mutational biosynthesis46) and chemical modification47^The main purpose for the construction of such derivatives is to enhance potency and spectrum and to lower toxicity of the compound(s). Of these derivatives, 5-oxime derivatives enhanced their potency in both avermectins and milbemycins48). 
Time (min)
The extraction of products and separation conditions were described in Fig. 8. "B" components is low. If the mutant strain produces 5-oxoavermectins directly, the 5-oxime derivatives would be easily and efficiently synthesized. In consideration of proposed biosynthetic pathway after formation of avermectin aglycones, if the step for C5 keto reduction is affected, the 5-oxoavermectin aglycones would be converted to the 5-oxoavermectins by stepwise glycosylation at C13 and C4' hydroxyl groups. During analysis of the region of aveD involving in C5 O-methylation, we identified the gene for C5 keto reduction step. Both genes for C5 O-methylation {aveD) and C5 keto reduction (aveF) were in the same operon. Wemodified the operon by the 8 bp-insertion, and the modified DNAsegment was introduced into the corresponding region on the chromosomeby a gene transreplacement technique using a temperature-sensitive replication plasmid vector. After double crossover recombination event occurs homologous region between the region of gene for C5 keto reduction on the chromosome and that on the recombinant plasmid, the recombinant plasmid was removedby growing at high temperature because the plasmid possessed phenotype of the temperaturesensitive replication. The products from mycelial extracts of transreplacement clones containing insertion mutation derived from wild-type strain were different from that of the wild-type strain and were identified as 5-oxoavermectins Bla, Bib, B2a, and B2b. Furthermore, we applied this technique for the construction of the selective producer K2021 (X) which possesses the mutation affecting the selectivity of the incorporation of branched-chain fatty acids into avermectin aglycones (accumulating "a" components). The expected transreplacement clones containing insertion mutation in the operon of aveD and aveF derived from the selective producer K2021 produced two components of 5-oxoavermectins Bla and B2a (Fig. ll) .
Selective Production of Avermectin B2a
In consideration of the biosynthetic pathway, we estimated that introduction of at least three mutations required to construct the single componentproducer into the avermectin biosynthetic pathway of the wild type strain. If three mutations, affecting to the O-methylation at C5 hydroxyl group (aveD), the selectivity of the incorporation of branched-chain fatty acid into the avermectin aglycones (X), and the dehydration between C22 and 23 residues (aveC), are introduced to the wild type strain, the resulting mutant let produce only avermectin B2a. Since avermectin B2a can be chemically transformed to 22,23-dihydroavermectin B l a, "Ivermectin Bla"50), the most potent anthelmintic compound51}, to design a single component producer of avermectin B2a is assumed to be more useful for industrial production of ivermectin Bla.
Since we had already constructed a recombinant strain K203823), a producer of avermectins Bla and B2a, by the protoplast fusion of two mutants, aveD and X construction of avermectin B2a producer might be accomplished by introduction of the mutation phenotype of dehydration between C22 and 23 (aveC) into the recombinant strain. As the entire gene cluster for avermectin biosynthesis had been already cloned, and also the region involving in C22,23-dehydration step (aveC) had been defined in a 4.82kbp-itaraHI segment at the center of the cluster by us, we attempted to introduce point mutation(s) in aveC region on the chromosome of the recombinant strain K2038. There are several procedures for the introduction of the random point mutation(s) into the cloned DNAsegment in vitro.
Wetried to introduce point mutation(s) into aveC region by using polymerase chain reaction (PCR). A part of the region of structural gene for aveC was subcloned, and then the segment was amplified by PCR in which concentrations ofdCTP, dGTPand dTTPwere increased to four-fold to be misincorporated deoxynucleotides into 
Retention time (min)
The mycelia from 1 0 ml-culture were extracted with equal volume of acetone and after removal of acetone by evaporation, products were extracted with methylenechloride. Methylenechloride extract was evaporated to dryness, the residue was dissolved in methanol and a portion of extract was directly applied to reversed phase silica gel HPLC.The separation conditions were described in ref. 
Suppression of the Accumulation of Useless Toxic
Compound, Oligomycin
The wild-type strain of S. avermitilis produces not only avermectins but also oligomycin. The selective producers of specific component(s) of avermectins, derived from the wild-type strain still produced useless compound, oligomycin. Being a toxic compound specifically inhibiting oxidative-phosphorylation in mammalian cells, oligomycin should be removed from mycelial extracts for the preparation of the commercial products.
In general, the desired mutant have been isolated from the wild-type strain by induction of mutation with chemical mutagens, radiation and so on. In this case, it is not easy to transfer the mutated phenotype to other strains.
We attempted to isolate the mutant by transposon-induced mutagenesis. Because the corre- Chromosomal fragments containing Tn4560 insertion in oligomycin biosynthetic genes were subcloned into a plasmid with temperature-sensitive replication and were used to carry transposon mutation to other strains, using the homologous recombination. The resulting transreplacement clones did not produce any oligomycin without affecting production of avermectins34). This technique can be used to construct an avermectin-producing strain that no longer makes the toxic oligomycin.
For example, the transfer of oligomycin-nonproducing phenotype was applied to two selective producers K2038 (aveD X) producing avermectins Bla and B2a, and K2099 (aveC aveD X) producing avermectin B2a (Fig. 1 3) . The resulting transreplacement clones produced avermectins Bla and B2a, and only B2a, respectively34'52*. This obviates the need for separation of avermectin and oligomycin.
III. Conclusion
Nowwe have elucidated the pathway for avermectin biosynthesis and cloned all genes for avermectin biosynthesis.
Furthermore, we are able to introduce mutation (s) in each step of avermectin biosynthesis in vitro from the knowledge ofavermectin biosynthesis. This means that it is possible to control the biosynthetic pathway and to design the producer which produces specific component(s) by the combination of mutations in avermectin biosynthesis. The attempt of these techniques might be applied to not only avermectin producer but also other metabolite-producing microorganisms, and it might be useful for the studies on biosynthesis of secondary metabolites and the construction of selective producer of valuable component in the industrial field.
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